Therapeutics Company Announces Collaboration With Oncology Firm
Haystack Oncology and Lisata Therapeutics Collaborate on Evaluating Pancreatic Cancer Therapy Efficacy Using MRD Technology.
Haystack Oncology announced a research collaboration with Lisata Therapeutics Inc. This partnership aims to leverage Haystack's cutting-edge minimal residual disease (MRD) technology to assess the efficacy of innovative treatments for metastatic pancreatic cancer.$Lisata Therapeutics (LSTA.US)$